Sympathectomy in refractory ventricular arrhythmias in patients with left ventricular assist device: a grand round case report
Abstract
Abstract Background Ventricular tachycardias (VTs) are a life-threatening complication of patients with end-stage left ventricular dysfunction, and are a frequent cause for considering advanced therapies. Their management in patients supported by a left ventricular assist device (LVAD) presents unique challenges, requiring a multidisciplinary approach to tailored strategies. Case summary We present the case of a 70-year-old male with a history of VTs who underwent HeartMate 3 (Abbott, USA) implantation for advanced heart failure secondary to ischaemic cardiomyopathy and refractory VTs. Following LVAD implantation, he developed an electrical storm refractory to a combination of antiarrhythmic drugs and both radiofrequency and pulse-field catheter ablations. Due to persistent VT, neuromodulation of the sympathetic nervous system was considered as a last-resort strategy. Percutaneous radiofrequency ablation of the stellate ganglion was unsuccessful; however, left surgical sympathectomy effectively controlled the arrhythmias. The patient has remained free of arrhythmic events at 1-year follow-up. Discussion Management of VTs in LVAD carriers is typically stepwise, beginning with correction of reversible triggers and the use of antiarrhythmic drugs. However, monotherapy is often insufficient, and achieving arrhythmic control often depends on a multimodal approach. In cases refractory to conventional measures, escalation to catheter ablation, neuromodulation techniques, and…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.